1. 国立がん研究センターがん情報サービスのがん登録・統計 (2018) https://ganjoho.jp/reg_stat/statistics/stat/summary.html
2. 胃癌治療ガイドライン 医師用 2018 年 1 月改訂 第 5 版、日本胃癌学会
3. 厚生労働省の第 5 回 NDB オープンデータ https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177221_00008.html
4. 山岡 雄祐、藤谷 和正、平尾 素宏、他 「胃全摘術後の低体重(BMI<18.5kg/m2)と関連する因子の検討」日外科系連会誌 38:726–731,2013
5. Kundes MF, Kement M, Yegen F et al. Effects of clinical factors on quality of life following curative gastrectomy for gastric cancer. Niger J Clin Pract. 2019; 22: 661-668.
6. Aoyama T, Sato T, Maezawa Y, et al. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer. Int J Clin Oncol. 2017; 22: 476-483.
7. Fujiwara Y, Fukuda S, Tsujie M, et al. Outcome predictors for patients with stage II/III gastric cancer who undergo gastrectomy and S-1 adjuvant chemotherapy. Oncol Lett. 2017; 14: 1621-1627.
8. Liedman B, Andersson H, Berglund B, et al. Food intake after gastrectomy for gastric carcinoma: the role of a gastric reservoir. Br J Surg. 1996; 83: 1138-1143.
9. Liedman B. Symptoms after total gastrectomy on food intake, body composition, bone metabolism, and quality of life in gastric cancer patients--is reconstruction with a reservoir worthwhile? Nutrition 1999; 15: 677-682.
10. McCarty TR, Jirapinyo P, Thompson CC. Effect of Sleeve Gastrectomy on Ghrelin, GLP-1, PYY, and GIP Gut Hormones: A Systematic Review and Meta-analysis. Ann Surg. 2019.
11. Koizumi M, Hosoya Y, Dezaki K et al. Serum ghrelin levels partially recover with the recovery of appetite and food intake after total gastrectomy. Surg Today 2014; 44: 2131-2137.
12. Kojima M, Kangawa K, Ghrelin: structure and function. Physiol Rev. 2005; 85: 495-522.
13. Fujimiya M, Ataka K, Asakawa A, et al. Ghrelin, des-acyl ghrelin and obestatin on the gastrointestinal motility. Peptides. 2011; 32: 2348-2351.
14. Delhanty PJ, Neggers SJ, van der Lely AJ. Mechanisms in endocrinology: Ghrelin: the differences between acyl- and des-acyl ghrelin. Eur J Endocrinol. 2012; 167: 601-608.
15. Ueno H, Yamaguchi H, Kangawa K, et al. Ghrelin: a gastric peptide that regulates food intake and energy homeostasis. Regul Pept. 2005; 126: 11-19.
16. van der Lely AJ, Tschöp M, Heiman ML, et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004; 25: 426-457.
17. Méquinion M, Langlet F, Zgheib S, et al. Ghrelin: central and peripheral implications in anorexia nervosa. Front Endocrinol. 2013; 4: 15.
18. Howick K, Griffin BT, Cryan JF, et al. From belly to brain: targeting the ghrelin receptor in appetite and food intake regulation. Int J Mol Sci. 2017; 18: E273.
19. Jeon TY, Lee S, Kim HH, Kim YJ, Son HC, Kim DH et al. (2004). Changes in plasma ghrelin concentration immediately after gastrectomy in patients with early gastric cancer. J Clin Endocrinol Metab. 2004; 89: 5392–5396.
20. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
21. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908–913.
22. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001; 86: 5992.
23. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
24. Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab. 2015; 4: 437-460.
25. Yanagi S, Sato T, Kangawa K et al. The Homeostatic Force of Ghrelin. Cell Metab. 2018; 27: 786-804.
26. Kobelt P, Wisser AS, Stengel A, et al. Peripheral injection of ghrelin induces Fos expression in the dorsomedial hypothalamic nucleus in rats. Brain Res. 2008; 1204: 77-86.
27. Ueno H, Yamaguchi H, Kangawa K, et al. Ghrelin: a gastric peptide that regulates food intake and energy homeostasis. Regul Pept. 2005; 126: 11-19.
28. Stark R, Ashley SE, Andrews ZB. AMPK and the Neuroendocrine Regulation of Appetite and Energy Expenditure. Mol Cell Endocrinol. 2013; 366: 215-223.
29. Adachi S, Takiguchi S, Okada K, et al. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology 2010; 138: 1312-1320.
30. Soleyman-Jahi S, Abdirad A, Fallah AA, et al. Prognostic Significance of Preoperative and Postoperative Plasma Levels of Ghrelin in Gastric Cancer: 3-Year Survival Study. Clin Transl Gastroenterol. 2017; 8: e209.
31. Koizumi M, Dezaki K, Hosoda H, et al. Reconstruction-dependent recovery from anorexia and time-related recovery of regulatory ghrelin system in gastrectomized rats. Int J Pept. 2010; 2010: 365416.
32. Yoshimura M, Shiomi Y, Ohira Y, et al. Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. Eur J Pharmacol. 2017; 811: 30-37.
33. Shiomi Y, Ohira Y, Yoshimura M, Ozaki T, et al. Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. Eur J Pharmacol. 2018; 818: 148-157.
34. Cheng, Y, Prusoff, WH, Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22: 3099–3108.
35. Takiguchi S, Takata A, Murakami K, et al. Clinical application of ghrelin administration for gastric cancer patients undergoing gastrectomy. Gastric Cancer 2014; 17: 200-205.
36. Takachi K, Doki Y, Ishikawa O, et al. Postoperative ghrelin levels and delayed recovery from body weight loss after distal or total gastrectomy. J Surg Res. 2006; 130: 1-7.
37. Jeon TY1, Lee S, Kim HH, et al. Changes in plasma ghrelin concentration immediately after gastrectomy in patients with early gastric cancer. J Clin Endocrinol Metab. 2004; 89: 5392-5396.
38. Takiguchi S, Takata A, Murakami K, et al. Impact of synthetic ghrelin administration for patients with severe body weight reduction more than 1 year after gastrectomy: a phase II clinical trial. Surg Today 2016; 46: 379-385.
39. Hiura Y, Takiguchi S, Yamamoto K, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 2012; 118: 4785-4794.
40. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89: 2832-2836.
41. Doki Y, Takachi K, Ishikawa O, et al. Ghrelin reduction after esophageal substitution and its correlation to postoperative body weight loss in esophageal cancer patients. Surgery 2006; 139: 797-805.
42. Adachi S, Takiguchi S, Okada K, et al. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology 2010; 138: 1312–1320.
43. Howick K, Alam R, Chruscicka B, et al. Sustained-release multiparticulates for oral delivery of a novel peptidic ghrelin agonist: formulation design and in vitro characterization. Int J Pharm. 2018; 536: 63-72.
44. Shiomi Y, Yoshimura M, Hori Y et al. Z-505, an Oral Ghrelin Receptor Agonist, Attenuates Anorexia After Total Gastrectomy in Rats. J Surg Res. 2020 Feb;246:527-534.
45. Fuoco D, Kilgour RD, Vigano A. A hypothesis for a possible synergy between ghrelin and exercise in patients with cachexia: biochemical and physiological bases. Med Hypotheses 2015; 85: 927-933.
46. Gardelli C, Wada H, Ray A, et al. Identification and Pharmacological Profile of an Indane Based Series of Ghrelin Receptor Full Agonists. J Med Chem. 2018; 61: 5974-5987.
47. Al-Massadi O, Trujillo ML, Señaris R, et al. The vagus nerve as a regulator of growth hormone secretion. Regul Pept. 2011; 166: 3-8.
48. Katakami N, Uchino J, Yokoyama T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 2018; 124: 606-616.
49. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, Sixth Edition 2007. (Discussion)
50. Wang L, Saint-Pierre DH, Taché Y. Peripheral ghrelin selectively increases Fos expression in neuropeptide Y - synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett. 2002; 325: 47-51.
51. Rüter J, Kobelt P, Tebbe JJ, et al. Intraperitoneal injection of ghrelin induces Fos expression in the paraventricular nucleus of the hypothalamus in rats. Brain Res. 2003; 991: 26-33.
52. Hashimoto H, Fujihara H, Kawasaki M, et al. Centrally and peripherally administered ghrelin potently inhibits water intake in rats. Endocrinology 2007; 148: 1638-1647.
53. Takayama K, Johno Y, Hayashi K, et al. Expression of c-Fos protein in the brain after intravenous injection of ghrelin in rats. Neurosci Lett. 2007; 417: 292-296.
54 Willesen MG, Kristensen P, Rømer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999; 70: 306-316.
55. Fedonidis C, Alexakis N, Koliou X, et al. Long-term changes in the ghrelin-CB1R axis associated with the maintenance of lower body weight after sleeve gastrectomy. Nutr Diabetes 2014; 4: e127.
56. Wang Q, Tang W, Rao WS, et al. Changes of Ghrelin/GOAT axis and mTOR pathway in the hypothalamus after sleeve gastrectomy in obese type-2 diabetes rats. World J Gastroenterol. 2017; 23: 6231-6241.
57. Ishii M, Toda T, Ikarashi N, et al. Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver. Eur J Pharm Sci. 2014; 51: 180-188.